Insulin degludec does not increase antibody formation versus insulin glargine: an evaluation of phase IIIa trials
We examined insulin antibody formation in patients with type 1 (T1D) or type 2 diabetes (T2D) treated with once‐daily insulin degludec (IDeg) or insulin glargine (IGlar) to evaluate the impact of antibody formation on efficacy and safety. Insulin antibodies were measured using subtraction radioimmun...
| Main Authors: | , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Blackwell Publishing Ltd
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067686/ |